[Advance in Research of Angiotensin II and Its Receptor and Malignant Tumor].
Angiotensin AngII, a linear small peptide,which is composed of eight amino acids, is the main effectors of renin-angiotensin systen (Renin-angiotensin system, RAS). AngII, a main biopolypeptide of the RAS, has important pathophysiologic in effects participating in cardiac hypertrophy, vascular cell proproliferation, inflammation and tissue remodeling through G-protein-coupled receptors. In recent years, Ang II can promote tumor cell proliferation, tumor vessel formation and inhibit the differentiation of the tumor cells. This suggests that inhibit the production of AngII or block its effect is expected to become a new measure for the treatment of malignant tumors. This article reviews the advances in research on the relationship between AngII and its receptor and malignant tumor in recent years.
Graduate Student of Hebei Medical University, Shijiazhuang 050000, China.
Lulu
L
Sun
Department of Medical Oncology, Hebei Province Cancer Hospital, Shijiazhuang 050000, China.
Jian
J
Shi
D000804:Angiotensin II / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D011945:Receptors, Angiotensin / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
D011945:Receptors, Angiotensin; D000804:Angiotensin II
J Renin Angiotensin Aldosterone Syst. 2015 Mar;16(1):189-94
25354524
Clin Exp Metastasis. 2013 Aug;30(6):819-32
23591595
Biochimie. 2013 Jun;95(6):1110-9
23507428
Lancet. 1997 May;349 Suppl 2:SII13-5
9164441
Mol Cancer Ther. 2009 Dec;8(12):3255-65
19996275
Nihon Rinsho. 2012 Sep;70(9):1604-12
23012811
BMC Cancer. 2010 Feb 24;10:67
20181281
Am J Pathol. 2013 Feb;182(2):553-64
23219751
Horm Metab Res. 1999 Jul;31(7):429-34
10450835
Oncol Rep. 2012 Mar;27(3):783-90
22089256
Drug Saf. 2001;24(10):727-39
11676301
Br J Cancer. 2010 Nov 23;103(11):1698-705
21102591
J Clin Invest. 2003 Jul;112(1):67-75
12840060
Cancer Cell Int. 2010 Jun 28;10:19
20584290
PLoS One. 2013;8(3):e59918
23536895
EMBO J. 2000 Aug 1;19(15):4026-35
10921883
Clin Cancer Res. 2005 Apr 1;11(7):2686-94
15814650
Am J Health Syst Pharm. 2011 Nov 15;68(22):2139-46
22058100
J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):453-8
25092717
Adv Cancer Res. 2010;109:51-72
21070914
Am J Obstet Gynecol. 2004 May;190(5):1258-63
15167827
CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
22700443
Mol Clin Oncol. 2015 Nov;3(6):1295-1300
26807236
Eur J Endocrinol. 2002 Apr;146(4):567-72
11916627
J Cancer. 2016 Jan 01;7(2):184-91
26819642
Anticancer Res. 2015 Sep;35(9):4789-97
26254369
Carcinogenesis. 2008 Sep;29(9):1675-84
18632755
PLoS One. 2014 Jan 22;9(1):e86404
24466075
Cancer. 2008 Feb 15;112(4):748-57
18181094
Lab Invest. 2007 Feb;87(2):189-98
17318197
J Mol Endocrinol. 2003 Dec;31(3):359-72
14664700
Cancer Biol Ther. 2010 Feb;9(4):277-85
20026904
Can J Cardiol. 2014 Feb;30(2):188-94
24461920
Int J Cardiol. 2014 Dec 20;177(3):748-53
25465823
Oncol Rep. 2013 Jun;29(6):2408-14
23545945
Medicine (Baltimore). 2015 Jun;94(22):e887
26039117
Exp Mol Med. 2006 Oct 31;38(5):525-34
17079869
Clin Sci (Lond). 2011 Apr;120(8):307-19
21488224
Mol Med. 2015 Jul 27;21:626-36
26225830